HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Placebo-controlled, randomized clinical trial of azimilide for prevention of ventricular tachyarrhythmias in patients with an implantable cardioverter defibrillator.

AbstractBACKGROUND:
Although implanted cardioverter defibrillators (ICDs) effectively treat sustained ventricular tachyarrhythmias, up to 50% of ICD recipients eventually require concomitant antiarrhythmic drug therapy to prevent symptomatic arrhythmia recurrences and hence reduce the number of device therapies.
METHODS AND RESULTS:
A total of 633 ICD recipients were enrolled in a randomized, double-blind, placebo-controlled study to evaluate the effect of daily doses of 75 or 125 mg of azimilide on recurrent symptomatic ventricular tachyarrhythmias and ICD therapies. Total all-cause shocks plus symptomatic ventricular tachycardia (VT) terminated by antitachycardia pacing (ATP) were significantly reduced by azimilide, with relative risk reductions of 57% (hazard ratio [HR]=0.43, 95% CI 0.26 to 0.69, P=0.0006) and 47% (HR=0.53, 95% CI 0.34 to 0.83, P=0.0053) at 75- and 125-mg doses, respectively. The reductions in all-cause shocks with both doses of azimilide did not achieve statistical significance. The incidence of all appropriate ICD therapies (shocks or ATP-terminated VT) was reduced significantly among patients taking 75 mg of azimilide (HR=0.52, 95% CI 0.30 to 0.89, P=0.017) and those taking 125 mg of azimilide (HR=0.38, 95% CI 0.22 to 0.65, P=0.0004). Five patients in the azimilide groups and 1 patient in the placebo group had torsade de pointes; all were successfully treated by the device. One patient taking 75 mg of azimilide had severe but reversible neutropenia.
CONCLUSIONS:
Azimilide significantly reduced the recurrence of VT or ventricular fibrillation terminated by shocks or ATP in ICD patients, thereby reducing the burden of symptomatic ventricular tachyarrhythmia.
AuthorsPaul Dorian, Martin Borggrefe, Hussein R Al-Khalidi, Stefan H Hohnloser, Jose M Brum, Daljit S Tatla, Johannes Brachmann, Robert J Myerburg, David S Cannom, Michael van der Laan, Michael J Holroyde, Igor Singer, Craig M Pratt, SHock Inhibition Evaluation with azimiLiDe (SHIELD) Investigators
JournalCirculation (Circulation) Vol. 110 Issue 24 Pg. 3646-54 (Dec 14 2004) ISSN: 1524-4539 [Electronic] United States
PMID15533855 (Publication Type: Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • Anti-Arrhythmia Agents
  • Hydantoins
  • Imidazolidines
  • Piperazines
  • azimilide
Topics
  • Anti-Arrhythmia Agents (adverse effects, therapeutic use)
  • Defibrillators, Implantable
  • Double-Blind Method
  • Electric Countershock
  • Endpoint Determination
  • Female
  • Humans
  • Hydantoins
  • Imidazolidines (adverse effects, therapeutic use)
  • Male
  • Middle Aged
  • Piperazines (adverse effects, therapeutic use)
  • Secondary Prevention
  • Tachycardia, Ventricular (prevention & control, therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: